Prithviraj Bose, MD

All 4 FDA-approved JAK inhibitors for myelofibrosis have unique toxicity profiles that all patients and physicians should know, said Prithviraj Bose, MD.

Non-driver mutations can be informative for clinicians in the treatment of patients with myelofibrosis, as they may help guide transplantation decisions.

There are 4 JAK inhibitors approved for myelofibrosis, all of which are usable in certain situations depending on a patient’s clinical factors.

Interferons and other anemia-driven therapies for myelofibrosis are exciting for the future, according to Prithviraj Bose, MD.